Patent intelligence · US
US 11963953
Deuterated compounds for restoring mutant p53 function
Deuterated compounds for restoring mutant p53 function
Patent details — US 11963953
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2024
- Expiration
- Apr 18, 2044
- Applicant
- PMV PHARMACEUTICALS, INC.
- Claims
- 33
- CPC classes
- A61K, A61K31/454
Quick answer
US 11963953 (Deuterated compounds for restoring mutant p53 function) is held by PMV PHARMACEUTICALS, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PMV PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 33
- CPC classes
- A61K, A61K31/454
More from PMV PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428406
Methods and compounds for restoring mutant p53 function
granted -
US 12419880
Companion diagnostic tool for mutant p53 reactivating compounds
granted -
US 11938124
Combination therapy for treatment of cancer
granted -
US 11926632
Methods and compounds for restoring mutant p53 function
granted -
US 11814373
Methods and compounds for restoring mutant p53 function
granted -
US 11807644
Methods and compounds for restoring mutant p53 function
granted -
US 11731953
Methods and compounds for restoring mutant p53 function
granted
Frequently asked questions
What is US patent 11963953?
US 11963953 (Deuterated compounds for restoring mutant p53 function) is held by PMV PHARMACEUTICALS, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11963953?
PMV PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 11963953 expire?
Our index shows an expiration date of Apr 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.